FRTX · Fresh Tracks Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | $8.01M | $6.94M | $404.0K | $1.82M | $7.92M | $12.80M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $3.18M | $14.04M | $28.23M | $11.22M | $20.21M | $12.33M |
| SG&A | $11.18M | $14.43M | $12.42M | $11.58M | $12.17M | $7.50M |
| Total Operating Expenses | $14.37M | $28.48M | $40.65M | $22.80M | $19.34M | $21.27M |
| D&A | $41.0K | $30.0K | $22.0K | $10.0K | $49.0K | $151.0K |
| Operating Income | ($6.36M) | ($21.53M) | ($40.24M) | ($20.98M) | ($24.47M) | ($19.65M) |
| Interest Expense | $5.0K | $9.0K | $69.0K | $0 | $1.09M | - |
| Income Tax | - | - | - | - | - | $0 |
| Net Income | ($5.69M) | ($21.10M) | ($39.47M) | ($20.91M) | ($23.88M) | ($16.25M) |
| EPS - Basic | ($1.06) | ($7.51) | ($0.85) | - | - | - |
| EPS - Diluted | ($1.06) | ($7.51) | ($0.85) | - | - | - |
Balance Sheet
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.87M | $8.68M | $26.88M | $30.11M | $7.23M | $11.87M |
| Accounts Receivable | - | - | - | - | - | $1.13M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $406.0K | $571.0K | $1.60M | $568.0K | $2.25M | $412.0K |
| Current Assets | $11.55M | $10.08M | $29.60M | $33.53M | $17.97M | $49.20M |
| Total Assets | $11.59M | $10.27M | $29.72M | $33.63M | $18.14M | $52.34M |
| Current Liabilities | $1.66M | $3.08M | $4.81M | $6.35M | $10.50M | $3.58M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | - | - | $4.81M | $6.50M | $10.57M | - |
| Stockholders' Equity | $9.93M | $7.19M | $24.91M | $27.14M | $7.57M | $48.76M |
| Retained Earnings | ($172.16M) | ($166.47M) | ($145.37M) | ($105.89M) | ($84.98M) | ($442.06M) |
Cash Flow
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.34M) | ($19.34M) | ($36.15M) | ($20.03M) | ($35.98M) | ($8.39M) |
| Investing Cash Flow | $0 | ($47.0K) | ($36.0K) | $4.48M | $32.51M | ($7.67M) |
| Financing Cash Flow | $6.53M | $1.18M | $32.95M | $38.44M | $2.64M | $7.74M |
| CapEx | $0 | $47.0K | $36.0K | $23.0K | $12.0K | $36.0K |
| Free Cash Flow | ($4.34M) | ($19.38M) | ($36.18M) | ($20.06M) | ($35.99M) | ($8.42M) |
Ratios
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -79.4% | -310.2% | -9961.4% | -1151.3% | -309.1% | -153.4% |
| EBITDA margin | -78.9% | -309.7% | -9955.9% | -1150.7% | -308.4% | -152.3% |
| Net margin | -71.1% | -303.9% | -9770.8% | -1147.8% | -301.6% | -126.9% |
| Free cash flow margin | -54.2% | -279.2% | -8956.4% | -1100.8% | -454.6% | -65.8% |
| FCF / Net income | 0.76 | 0.92 | 0.92 | 0.96 | 1.51 | 0.52 |
| R&D / Revenue | 39.7% | 202.3% | 6987.9% | 615.6% | 255.3% | 96.3% |
| SG&A / Revenue | 139.7% | 207.9% | 3073.5% | 635.7% | 153.7% | 58.6% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -49.1% | -205.5% | -132.8% | -62.2% | -131.6% | -31.1% |
| Return on equity | -57.3% | -293.3% | -158.5% | -77.1% | -315.2% | -33.3% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 6.98 | 3.28 | 6.15 | 5.28 | 1.71 | 13.74 |
| Quick ratio | 6.98 | 3.28 | 6.15 | 5.28 | 1.71 | 13.74 |
| Cash ratio | 6.56 | 2.82 | 5.59 | 4.74 | 0.69 | 3.31 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -1272.0x | -2392.7x | -583.2x | - | -22.4x | - |
| Equity multiplier | 1.17 | 1.43 | 1.19 | 1.24 | 2.40 | 1.07 |
| Liabilities / Assets | - | - | 0.16 | 0.19 | 0.58 | - |
| Efficiency | ||||||
| Asset turnover | 0.69 | 0.68 | 0.01 | 0.05 | 0.44 | 0.24 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | 32d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 15.3% | 1618.6% | -77.8% | -77.0% | -38.2% | -7.3% |
| Revenue CAGR (3y) | 63.8% | -4.3% | -68.4% | -49.1% | -18.3% | -15.1% |
| Revenue CAGR (5y) | -9.0% | -12.9% | -51.2% | -38.6% | -12.3% | 10.7% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 70.5% | 46.5% | -91.9% | 14.3% | -24.5% | -46.8% |
| Net income growth (YoY) | 73.0% | 46.5% | -88.8% | 12.4% | -46.9% | -25.4% |
| EPS growth (YoY) | 85.9% | -783.5% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 77.6% | 46.4% | -80.4% | 44.3% | -327.3% | 3.0% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 38.0% | -71.1% | -8.2% | 258.3% | -84.5% | -23.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$16.01M totalProduct And Service Other$8.01M · 50.0%
Buyout Of Post Closing Obligations$7.94M · 49.6%
Sublicense Income$53.0K · 0.3%
Consulting Services$9.0K · 0.1%
Stability scores
Piotroski F-score
FY 2023 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Fresh Tracks Therapeutics against the 5 most active filers in the same SIC group.